Page last updated: 2024-10-27

gabexate and Cytokine Release Syndrome

gabexate has been researched along with Cytokine Release Syndrome in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhou, H1
Fang, Y1
Xu, T1
Ni, WJ1
Shen, AZ1
Meng, XM1

Reviews

1 review available for gabexate and Cytokine Release Syndrome

ArticleYear
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
    British journal of pharmacology, 2020, Volume: 177, Issue:14

    Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En

2020